Walleye Capital LLC Decreases Stake in Celcuity, Inc. $CELC

Walleye Capital LLC cut its holdings in shares of Celcuity, Inc. (NASDAQ:CELC) by 31.1% during the first quarter, HoldingsChannel.com reports. The fund owned 105,688 shares of the company’s stock after selling 47,601 shares during the period. Walleye Capital LLC’s holdings in Celcuity were worth $12,063,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Creative Planning acquired a new stake in Celcuity in the 2nd quarter valued at about $177,000. Rhumbline Advisers boosted its holdings in shares of Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after purchasing an additional 503 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Celcuity in the second quarter valued at approximately $169,000. Quantinno Capital Management LP grew its position in shares of Celcuity by 20.7% in the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after purchasing an additional 41,756 shares in the last quarter. Finally, Paloma Partners Management Co grew its position in shares of Celcuity by 285.8% in the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after purchasing an additional 60,849 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Insider Activity

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.33% of the company’s stock.

Celcuity Stock Performance

Shares of Celcuity stock opened at $90.14 on Thursday. The firm has a market cap of $4.40 billion, a PE ratio of -23.11 and a beta of 0.16. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a 52 week low of $13.59 and a 52 week high of $151.02. The business’s fifty day simple moving average is $106.07 and its 200-day simple moving average is $110.65.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. Equities analysts forecast that Celcuity, Inc. will post -3.76 earnings per share for the current year.

Analyst Ratings Changes

CELC has been the topic of a number of analyst reports. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Citigroup restated an “outperform” rating on shares of Celcuity in a report on Wednesday, July 15th. Leerink Partners set a $155.00 price target on Celcuity in a report on Tuesday, June 2nd. Craig Hallum reiterated a “buy” rating and set a $178.00 price target on shares of Celcuity in a report on Wednesday, July 15th. Finally, HC Wainwright upped their price objective on shares of Celcuity from $145.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity has an average rating of “Moderate Buy” and an average target price of $155.18.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.